Teva Raises 2026 Sales Forecast for Uzedy Following Strong Q3 Performance

Teva raised its 2026 U.S. sales forecast for Uzedy to $290 million–$310 million from $270 million–$290 million, its second increase this year. The schizophrenia treatment generated $85 million in third-quarter 2026 net sales, beating analyst consensus of $74 million. MedinCell receives 5%–10% royalties on sales and may earn up to $105 million in commercial milestone payments; growth has been supported by greater hospital access and more than 800 new monthly prescribers.